- Trial phase
- Phase 2
- Time to market
- Trevogrumab is in Phase 2 development with no Phase 3 trial or regulatory filing announced. If a Phase 3 program begins in 2027, potential approval would likely be several years away, assuming positive results.
- Why 3/10
- No hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months. The next milestone is a planned Phase 2 trial in older adults with obesity, but no start date has been announced. Trevogrumab is a Phase 2 asset at a large, diversified biotech where it represents a small fraction of overall value.
The next catalyst for trevogrumab is Regeneron's planned Phase 2 trial in older adults with obesity and decreased muscle mass/strength, but no start date has been announced. Investors should watch for trial initiation and any partnership or licensing activity in the muscle-preservation space, as well as competitive developments from Eli Lilly's bimagrumab (Phase 3) and Scholar Rock's apitegromab. Trevogrumab is unlikely to drive material share-price moves for REGN in the next 12 months given the lack of a hard dated binary catalyst and the drug's small weight within Regeneron's diversified pipeline.
Price Chart
Executive Summary
Trevogrumab (REGN1033) is Regeneron's investigational anti-myostatin monoclonal antibody being developed to preserve muscle mass during GLP-1 agonist-induced weight loss. The Phase 2 COURAGE trial (NCT06299098) met its endpoints, showing trevogrumab 75mg cut lean mass loss by roughly 42% versus semaglutide alone at 52 weeks, with thigh muscle preservation up to 71.8% on MRI. Results were presented at EASD in October 2026 and published in The Lancet. Regeneron plans a follow-up Phase 2 trial in older adults with obesity and low muscle mass, but no Phase 3 trial or regulatory filing has been announced. For a large-cap biotech like Regeneron (market cap ~$93B, many approved blockbusters), trevogrumab is an early-stage pipeline asset with no near-term binary catalyst.
How It Works
Trevogrumab is a lab-made antibody that blocks myostatin (also called GDF8), a protein the body naturally uses to limit muscle growth. By neutralizing myostatin, the drug allows the body to hold onto or build muscle, even during the calorie deficit caused by weight-loss drugs like semaglutide (Wegovy).
Trial Status
The Phase 2 COURAGE trial (NCT06299098) has completed its primary analyses. The 52-week results were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting on October 1, 2026, and are in press with The Lancet. The trial enrolled 1,005 patients with obesity and tested trevogrumab at various doses (25mg, 75mg, 200mg, 400mg) in combination with semaglutide 2.4mg, with and without garetosmab (anti-activin A). Regeneron plans to initiate a new Phase 2 trial in older adults with obesity and decreased muscle mass and/or strength.
The Two-Sided Case
Upcoming Catalysts
- Initiation of a Phase 2 trial in older adults with obesity and decreased muscle mass/strength (date not yet announced)
- Any potential partnership or licensing deals for muscle-preservation assets
- Competitive readouts from Eli Lilly's bimagrumab (Phase 3) and Scholar Rock's apitegromab
Source Filing
The SecBot filing or press-release report that triggered this drug report:
REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report